LA JOLLA, Calif.--(BUSINESS WIRE)--Regulus Therapeutics Inc. today announced that new pre-clinical data from its therapeutic programs will be presented at the jointly held Keystone Symposia “microRNAs and Non-coding RNAs and Cancer” and “microRNAs and Human Disease” held February 11-16, 2011 in Banff, Alberta, Canada. Regulus and its collaborators will present advancements from multiple programs including new data from Regulus’ oncology program showing anti-miRs targeting microRNA-21 provide a significant survival advantage in a mouse model of hepatocellular carcinoma.
